Publishing House SB RAS:

Publishing House SB RAS:

Address of the Publishing House SB RAS:
Morskoy pr. 2, 630090 Novosibirsk, Russia



Advanced Search

The journal "Ateroskleroz"

2016 year, number 4

POLYMORPHISM IN GENES INVOLVED IN LIPID METABOLISM IN MODY PATIENTS

M. I. Voevoda1,2, E. V. Shakhtshneider1, A. K. Ovsyannikova1, O. D. Rymar1, D. E. Ivanoshchuk1,2, A. M. Kurilshikov3, Yu. I. Ragino1
1Institute of Internal and Preventive Medicine, Novosibirsk, Russia
2Institute Cytology and Genetics, RAS, Novosibirsk, Russia
3Institute of Chemical Biology and Fundamental Medicine, RAS, Novosibirsk, Russia
Keywords: сахарный диабет, сахарный диабет зрелого типа у молодых, гиперлипидемия, полиморфизм генов, maturity onset diabetes of the young, hyperlipidemia, polymorphism, genes

Abstract

We have analyzed the lipid profile and polymorphism in the genes involved in lipid metabolism in patients with maturity onset diabetes of the young (MODY) in West Siberia, Russia. MODY is a heterogeneous group of disorders caused by mutations in different autosomal dominant genes with high penetration. MODY is characterized by a slow onset of symptoms, the absence of obesity, no ketosis, and no evidence of beta cell autoimmunity. Materials and methods: In the Clinical-Diagnostic Department of the Institute of Internal and Preventive Medicine, the eligible patients underwent a clinical examination, biochemical blood analysis, quantification of HbA1c, C-peptide, thyroid status, microalbuminuria testing, ultrasonography of the abdomen and kidneys, and blood glucose monitoring (MiniMed Paradigm, MMT-754). MODY2 diabetes was confirmed in 5 patients; MODY3, in 2 patients; MODY6, in 1 patient; MODY8, in 2 patients; MODY12, in 1 patient by sequencing. The plasma lipid levels were determined by standard enzymatic assays. The lipid metabolism genes ( APOA1, APOA2, APOA4, APOA5, APOB, APOC3, APOD, LDLR, LDLRAP1, LPL, PCSK9, SCARB1 and SREBF2 ) were analyzed. Results: Hyperlipidemia was detected in patients with MODY (MODY1, MODY2, MODY3 subtypes). We found the Pro434Gln polymorphism the SREBF2 gene exon 7 and the Gly2Ser polymorphism in the SCARB1 gene exon 1. We detected the Ser474Ter nonsense-mutation the LPL gene exon 9 in 2 patients. Conclusion: Polymorphism in the genes involved in lipid metabolism can cause the lipid disorder in MODY patients. Sequencing of the genes improved our understanding of the molecular basis of MODY phenotype and may help to provide the future personalized therapy.